Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma
- Abstract
- Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma
- Issued Date
- 2022
- Type
- Article
- Publisher
- EUROPEAN JOURNAL OF CANCER
- Language
- 영어
- ISSN
- 0959-8049
- Citation Volume
- 163
- Citation Number
- 0
- Citation Start Page
- 55
- Citation End Page
- 65
- 파일 목록
-
-
관련 파일이 존재하지 않습니다.
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.